

The meetings are open to the public, but pre-registration is required. Any individual who wishes to attend the meeting should register via email at stephanie@womensvote100.org or telephone 202-707-0106.

Interested persons may choose to make a public comment at the meeting during the designated time for this purpose. Public comments shall be limited by minutes based on the number of participants signed up to comment for the allotted time, and subject to agenda time changes based on the speed of the commission's work through the agenda. Speakers who wish to expand upon their oral statements, or those who had wished to speak but could not be accommodated on the agenda, may submit written statements up to 30 days after the meeting.

Members of the public may also choose to submit written comments by mailing them to Stephanie Marsellos, Designated Federal Officer, P.O. Box 2020, Washington, DC 20013, or via email at stephanie@womensvote100.org. Please contact Ms. Marsellos at the email address above to obtain meeting materials. All written comments received will be provided to the Commission. Detailed minutes of the meeting will be available for public inspection within 90 days of the meeting.

Individuals requiring special accommodations to access the public meeting should contact Ms. Marsellos at least five business days prior to each meeting, so that appropriate arrangements can be made.

Public Disclosure of Comments

Before including your address, phone number, email address, or other personally identifiable information (PII) in your comment, you should be aware that your entire comment—including your PII—may be made publicly available at any time.

While you can ask us in your comment to withhold your PII from public review, we cannot guarantee that we will be able to do so.

Dated: September 9, 2020.

David Coscia,

Agency Liaison Officer, Office of Presidential & Congressional Agency Liaison Services, Office of Administrative Services.

[FR Doc. 2020-20803 Filed 9-18-20; 8:45 am]

BILLING CODE 3420-37-P

GENERAL SERVICES ADMINISTRATION

[Notice—MA—2020—11; Docket No. 2020—0002; Sequence No. 30]

Relocation Allowances—Waiver of Certain Federal Travel Regulation (FTR) Provisions for Renewal Agreement Travel (RAT) During the COVID-19 Pandemic

AGENCY: Office of Government-wide Policy (OGP), General Services Administration (GSA).

ACTION: Notice of GSA Bulletin FTR 21-02.

SUMMARY: This FTR bulletin informs agencies that certain FTR provisions governing RAT are temporarily waived as a result of impacts to travel from the Coronavirus Disease 2019 (COVID-19).

DATES: *Applicability Date:* This notice is retroactively effective for employees whose official RAT was delayed or suspended after March 13, 2019 (one year prior to the date of the national emergency issued by the President concerning COVID-19), and who have not yet taken RAT.

FOR FURTHER INFORMATION CONTACT: For clarification of content, contact Mr. Rodney (Rick) Miller, Senior Program Analyst, Office of Government-wide Policy, Office of Asset and Transportation Management, at 202-501-3822, or by email at travelpolicy@gsa.gov. Please cite Notice of FTR Bulletin 21-02.

SUPPLEMENTARY INFORMATION:

Background: Federal agencies authorize relocation entitlements to those individuals listed at FTR § 302-1.1. Such individuals must sign a service agreement stating that the individual agrees to serve for a minimum time period after they have relocated, and as prescribed in FTR § 302-2.14. Before successfully completing the initial tour of duty, an agency may offer RAT for an employee to serve a new tour of duty at the same or different OCONUS location, if the employee agrees to the conditions under FTR § 302-3.212.

As a result of COVID-19, employees and their immediate family members may be, or may have been, required to delay taking RAT despite the employee's successful completion of their initial tour of duty and commitment to a second overseas tour of duty. As a result of the delay, employees might not have 12 months remaining in their second tour of duty upon their return from RAT as prescribed at FTR §§ 302-2.14(d) and 302-3.505(d)). Accordingly, agencies

may waive FTR §§ 302-2.14(d) and 302-3.505(d), meaning that RAT travelers are not required to have 12 months of service remaining on their second overseas tour of duty after taking RAT, in order to be eligible for RAT. The requirements at FTR §§ 302-3.223 and 302-3.224 remain in effect. This bulletin can be viewed at <https://www.gsa.gov/ftrbulletins>.

Jessica Salmoiraghi,

Associate Administrator, Office of Government-wide Policy.

[FR Doc. 2020-20683 Filed 9-18-20; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Agency Information Collection Activities: Proposed Collection; Comment Request; Voluntary Customer Survey Generic Clearance for the Agency for Healthcare Research and Quality

AGENCY: Agency for Healthcare Research and Quality, HHS.

ACTION: Notice.

SUMMARY: This notice announces the intention of the Agency for Healthcare Research and Quality (AHRQ) to request that the Office of Management and Budget (OMB) approve the proposed information collection project:

“*Voluntary Customer Survey Generic Clearance for the Agency for Healthcare Research and Quality.*” This proposed information collection was previously published in the **Federal Register** on June 11, 2020 and allowed 60 days for public comment. AHRQ received no substantive comments. The purpose of this notice is to allow an additional 30 days for public comment.

DATES: Comments on this notice must be received 30 days after date of publication.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.

FOR FURTHER INFORMATION CONTACT:

Doris Lefkowitz, AHRQ Reports Clearance Officer, (301) 427-1477, or by email at doris.lefkowitz@AHRQ.hhs.gov.

SUPPLEMENTARY INFORMATION: